Table 3. Cox proportional hazards models of effect of locoregional therapy.
| Variable | HR | 95%CI | P value |
|---|---|---|---|
| Grade | |||
| 2 | 1.411 | 0.866–2.301 | 0.167 |
| 3 | 1.000 | ||
| Charlson comorbidity index | |||
| ≤2 | 1.078 | 0.701–1.657 | 0.732 |
| ≥3 | 1.000 | ||
| Hormone receptor | |||
| Positeve | 1.000 | ||
| Negative | 2.109 | 1.375–3.235 | 0.001 |
| Her-2 receptor | |||
| Positive | 1.154 | 0.766–1.739 | 0.492 |
| Negative | 1.000 | ||
| Systemic therapy efficacy | |||
| CR | 0.347 | 0.171–0.702 | 0.003 |
| PR | 0.688 | 0.405–1.170 | 0.167 |
| SD | 1.000 | ||
| Osseous metastasis | |||
| Yes | 2.377 | 1.367–4.134 | 0.002 |
| No | 1.000 | ||
| Cerebral metastasis | |||
| Yes | 1.000 | ||
| No | 0.483 | 0.483 | 0.029 |
| Softtissue metastasis | |||
| Yes | 1.000 | ||
| No | 3.651 | 1.924–6.794 | <0.001 |
| Locoregional therapy | |||
| Surgery + radiation therapy + systemic therapy | 0.219 | 0.090–0.529 | 0.001 |
| Radiation therapy + systemic therapy | 0.362 | 0.148–0.885 | 0.026 |
| Systemic therapy alone | 0.438 | 0.190–1.012 | 0.053 |
| No therapy | 1.000 | ||
HR-Hazard ratio,CI-confidence interval, CR-complete remission,PR-partial remission,SD-stable disease, HER-human epidermal growth factor receptor.